    1.14.13.9 | purified full-length structure of KMO in its membrane-embedded form complexed with inhibitors 2-(benzyloxy)-5-[5-(4-chloro-3-fluorophenyl)-4-methyl-1H-pyrazol-1-yl]benzoic acid or 4-chloro-2-([5-chloro-2-(5-methoxy-1,3-dihydro-2H-isoindol-2-yl)-1,3-thiazole-4-carbonyl](methyl)amino)-5-fluorobenzoic acid, sitting drop vapour diffusion method, mixing of enzyme in lipidic cubic phase formed by mixing a 9:1 monoolein:cholesterol molten lipid mixture and inhibitors, with reservoir solution containing 0.04 M Tris-Cl, pH 7.0, 0.06 M Bis-Tris, pH 6.5, 0.3-0.51 M lithium sulfate, and 34-45% PEG 400 for 2-(benzyloxy)-5-[5-(4-chloro-3-fluorophenyl)-4-methyl-1H-pyrazol-1-yl]benzoic acid and containing 0.04-0.05 M sodium citrate, pH 6.5, or 0.04 M Bis-Tris pH 6.5, 0.05-0.06 M Tris-Cl, pH 7.0, 0.12-0.43 M lithium sulfate, and 34-46% PEG 400 for 4-chloro-2-([5-chloro-2-(5-methoxy-1,3-dihydro-2H-isoindol-2-yl)-1,3-thiazole-4-carbonyl](methyl)amino)-5-fluorobenzoic acid, in a 2:3 ratio at 17°C for 1-3 days, X-ray diffraction structure determination and analysis at 3.0 A resolution |
